Akston Biosciences, a United States-based company that deals with insulin engineering, has collaborated with LakePharma, a United States-based CRDMO serving the biotechnology community, to produce commercial quantities of Akston's adjuvated COVID-19 vaccine candidate, AKS-452, it was reported on Tuesday.
The vaccine candidate is scheduled to commence phase 1/2 clinical testing later this month.
AKS-452 is a COVID-19-specific Fc fusion protein vaccine that is in commercial development and is designed to induce or boost a Th1/Th2 mixed immune response in patients against the Receptor Binding Domain of the novel SARS-CoV-2 coronavirus spike protein. It is shelf-stable for weeks at up to 37 degrees Celsius and is engineered to use conventional antibody manufacturing techniques.
Dicot Pharma receives FDA clearance to start Phase 2b study of LIB-01 in US
CeleCor Therapeutics submits final section of zalunfiban (Disaggpro) New Drug Application to US FDA
Vascarta announces VAS-101 Phase I results in sickle cell disease patients
Cirius Therapeutics commences enrolment and dosing for Phase 2 study of CIR-0602K in type 1 diabetes
Lundbeck to present new Vyepti and bocunebart migraine data at EAN 2026
Thalia Therapeutics acquires Sanmirna and raises GBP2.75m to advance AML RNA therapy
Circio and Tcelltech partner on next-generation CAR-T cell therapy research
Essange Reagents and Gentian Diagnostics agree collaboration on diagnostic assay development
Haisco agrees licensing deal with Nuvectis for two drug candidates
Psilera introduces new synthetic platform to aid neuroplastogen discovery
EU approves MAVIRET for acute hepatitis C treatment
EU approves Cenrifki for secondary progressive multiple sclerosis without relapses
Japan approves Wayrilz for immune thrombocytopenia treatment
Nura Bio completes USD73.8m Series B financing, advances clinical-stage SARM1 inhibitor programmes
Oxford BioTherapeutics reports progress in Boehringer Ingelheim partnered programmes